免疫相关性心肌炎2例报道及文献复习
Immune Associated Myocarditis: A Report of 2 Cases and Literature Review

DOI: 10.12677/ACREM.2020.83009, PP. 25-29

Keywords: 免疫相关性心肌炎，激素
Immune Associated Myocarditis, Hormone

Full-Text   Cite this paper   Add to My Lib

Abstract:

随着免疫治疗时代来临，免疫相关性一些疾病随之出现，免疫相关性心肌炎临床比较少见，容易漏诊误诊，治疗不及时或失治误治往往会对肿瘤患者造成生命危险。为提高该病在临床上的诊治率，通过这2例患者的诊治经过，来说明免疫相关性心肌炎治疗中激素应用时间的重要性。
With the advent of the immunotherapy era, some immune related diseases appear. Immune associated myocarditis is rare, it is easy to miss diagnosis and misdiagnosis. Untimely treatment or mistreatment will cause life dangerous to patients. In order to improve the clinical diagnosis and treatment rate of the disease, through the diagnosis and treatment of these two patients to illustrate the importance of hormone application time in the treatment of immune associated myocarditis.

References

[1]	Zhao, L.F. and Fu, Z.Y. (2018) Roles of Host Immunity in Viral Myocarditis and Dilated Cardiomyopathy. Journal of Immunology Research, 2018, Article ID: 5301548. https://doi.org/10.1155/2018/5301548
[2]	Sznol, M., Postow, M.A., Davies, M.J., et al. (2017) Endocrine-Related Adverse Events Associated with Immune Checkpoint Blockade and Expert Insights on Their Management. Cancer Treatment Reviews, 58, 70-76. https://doi.org/10.1016/j.ctrv.2017.06.002
[3]	Hassel, J.C., Heinzerling, L., Aberle, J., et al. (2017) Combined Immune Checkpoint Blockade (Anti-PD-1/Anti-CTLA-4): Evaluation and Management of Adverse Drug Reactions. Cancer Treatment Reviews, 57, 36-49. https://doi.org/10.1016/j.ctrv.2017.05.003
[4]	Esfahani, K., Buhlaiga, N., Thébault, P., Lapointe, R., Johnson, N.A. and Miller Jr., W.H. (2019) Alemtuzumab for Immune-Related Myocarditis Due to PD-1 Therapy. The New Eng-land Journal of Medicine, 380, 2375-2376. https://doi.org/10.1056/NEJMc1903064
[5]	Wang, Y., Zhou, S., Yang, F., et al. (2019) Treatment-Related Ad-verse Events of PD-1 and PD-L1 Inhibitors in Clinical Trials: A Systematic Review and Meta-Analysis. JAMA Oncology, 5, 1008-1019. https://doi.org/10.1001/jamaoncol.2019.0393
[6]	Brumbaugh, A.D., Narurkar, R., Parikh, K., Fanucchi, M. and Frishman, W.H. (2019) Cardiac Immune-Related Adverse Events in Immune Checkpoint Inhibition Therapy. Cardiology in Review, 27, 97-107. https://doi.org/10.1097/CRD.0000000000000217
[7]	Weinmann, S.C. and Pisetsky, D.S. (2019) Mechanisms of Immune-Related Adverse Events during the Treatment of Cancer with Immune Checkpoint Inhibitors. Rheumatology, 58, vii59-vii67. https://doi.org/10.1093/rheumatology/kez308
[8]	Varricchi, G., Galdiero, M.R., Marone, G., et al. (2017) Cardio-toxicity of Immune Checkpoint Inhibitors. ESMO Open, 2, e000247. https://doi.org/10.1136/esmoopen-2017-000247
[9]	Moslehi, J.J., et al. (2018) Increased Reporting of Fatal Im-mune Checkpoint Inhibitor-Associated Myocarditis. The Lancet, 391, 933. https://doi.org/10.1016/S0140-6736(18)30533-6
[10]	Mahmood, S.S., Fradley, M.G., Cohen, J.V., et al. (2018) Myocarditis in Patients Treated with Immune Checkpoint Inhibitors. Journal of the American College of Cardiology, 71, 1755-1764. https://doi.org/10.1016/j.jacc.2018.02.037
[11]	Wang, P.F., Chen, Y., Song, S.Y., et al. (2017) Im-mune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. Fron-tiers in Pharmacology, 8, 730. https://doi.org/10.3389/fphar.2017.00730

Full-Text